<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03253536</url>
  </required_header>
  <id_info>
    <org_study_id>Livercare</org_study_id>
    <nct_id>NCT03253536</nct_id>
  </id_info>
  <brief_title>Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma</brief_title>
  <acronym>LIVERCARE</acronym>
  <official_title>Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective single arm, single center observational study to evaluate Quality of Life (Qol)
      after stereotactic body radiotherapy for patients with hepatocellular cancer. Patients will
      receive work-up, treatment and follow-up exclusively as routinely done except additional
      quality of life measurements. Qol will be measured by standardized and validated EORTC
      questionaires at different time points during routine follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective single arm, single center observational study to evaluate Quality of Life (Qol)
      after stereotactic body radiotherapy (SBRT) for patients with hepatocellular cancer (HCC).
      Patients will receive work-up, treatment and follow-up exclusively as routinely done except
      additional quality of life measurements. This will include contrast-enhanced liver MRI or CT
      and placement of fiducials if necessary. Radiation treatment planning will be based on
      contrast-enhanced fourdimensional computed tomography (4D-CT) with abdominal compression.
      Target volume definition will use an internal target volume (ITV) concept. Dose prescription
      and fractionation will be prescribed individually based on lesion size, localisation,
      movement and liver function according to institutional standards. Qol will be measured by
      standardized and validated EORTC questionaires (QLQ C-30 and HCC 18) at baseline, at the end
      of SBRT, during follow up at 6 weeks, 3,6,12,24,36,48 and 60 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2017</start_date>
  <completion_date type="Anticipated">July 10, 2027</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>60 months</time_frame>
    <description>Quality of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>acute toxicity</measure>
    <time_frame>3 months</time_frame>
    <description>physician-related acute toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late toxicity</measure>
    <time_frame>6, 12, 24, 36, 48, 60 months</time_frame>
    <description>physician-related late toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response</measure>
    <time_frame>3 months</time_frame>
    <description>response to treatment according to imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local control</measure>
    <time_frame>60 months</time_frame>
    <description>absence of regrowth inside the treated lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatic control</measure>
    <time_frame>60 months</time_frame>
    <description>absence of regrowth or onset of new lesions inside the liver</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant control</measure>
    <time_frame>60 months</time_frame>
    <description>absence of extrahepatic progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>freedom from treatment failure</measure>
    <time_frame>60 months</time_frame>
    <description>absence of disease progression other than death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>60 months</time_frame>
    <description>absence of death of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pattern of recurrence</measure>
    <time_frame>60 months</time_frame>
    <description>pattern of recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation Qol with acute toxicity</measure>
    <time_frame>3 months</time_frame>
    <description>correlation Qol with acute toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation Qol with late toxicity</measure>
    <time_frame>6, 12, 24, 36, 48, 60 months</time_frame>
    <description>correlation Qol with late toxicity</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatocellular Cancer</condition>
  <condition>Quality of Life</condition>
  <condition>Stereotactic Body Radiation Therapy</condition>
  <condition>Observational</condition>
  <arm_group>
    <arm_group_label>entire cohort</arm_group_label>
    <description>none (observational study)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>observational</intervention_name>
    <description>none (observational study)</description>
    <arm_group_label>entire cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adult patients receiving routine SBRT to 1-3 intrahepatic HCC lesions
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically or radiologically proven hepatocellular carcinoma

          -  1-3 lesions suitable for stereotactic radiation therapy

          -  indication for SBRT according to multidisciplinary board evaluation

          -  age &gt;= 18 years

          -  written informed consent for study participation

          -  mental and verbal ability to complete standardized questionaires according to
             assessment by investigator (physician)

        Exclusion Criteria:

          -  age &lt; 18 years

          -  prior HCC specific systemic therapy

          -  concurrent oncological systemic treatment

          -  distant metastases

          -  inadequate ability tobe compliant with the protocol or to complete standardizes
             questionaires

          -  inability to receive contrast-enhanced planning CT

          -  missing ability to give informed consent

          -  legal custody
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Falk Roeder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, University Hospital, LMU Munich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Falk Roeder, MD</last_name>
    <phone>+49 89 4400 73729</phone>
    <email>Falk.Roeder@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabine Gerum, MD</last_name>
    <phone>+49 89 4400 73729</phone>
    <email>Sabine.Gerum@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiation Oncology, University Hospital, LMU Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Falk Roeder, MD</last_name>
      <phone>+49 89 4400 73729</phone>
      <email>Falk.Roeder@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Gerum, MD</last_name>
      <phone>+49 89 4400 73729</phone>
      <email>Sabine.Gerum@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Ladan Saleh-Ebrahimi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franziska Walter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Hoffmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra Jensen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2017</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2017</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Falk Roeder</investigator_full_name>
    <investigator_title>Consultant Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular Cancer</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>stereotactic body radiation therapy</keyword>
  <keyword>observational</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

